Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucinex SE
- Development stage
- Phase 1
- Lead developer
- RB Health (US)
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Mucinex SE** is an over-the-counter extended-release bi-layer tablet formulation containing 600 mg guaifenesin per tablet, designed to provide immediate and extended relief from chest congestion for up to 12 hours. Guaifenesin acts as an expectorant by thinning and loosening mucus in the airways, facilitating its expulsion through coughing and improving mucociliary clearance. Developed and marketed by RB Health (US) LLC under the Mucinex brand, it is indicated for symptomatic relief of productive coughs associated with colds, bronchitis, and other respiratory conditions, and is taken orally every 12 hours without regard to meals.[1][2][5]
- Brand names
- Mucinex SE
Beyond the preview
Go deeper on Mucinex SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucinex SE.